HSTO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 22:45):

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products...

Stats
Šios dienos apimtis	85.00
Vidutinė apimtis	18 354.00
Rinkos kapitalizacija	854 352
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $0 ) 2024-06-19
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0700
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-20	Windham-bannister Susan Richards	Buy	6 835	Stock Option (right to buy)
2023-06-20	Satz Brian	Buy	6 835	Stock Option (right to buy)
2023-06-20	Kisner Daniel L	Buy	6 835	Stock Option (right to buy)
2023-06-20	Jackson Jonathan	Buy	6 835	Stock Option (right to buy)
2023-06-20	Fuhrmann Rochelle	Buy	6 835	Stock Option (right to buy)

INSIDER POWER
76.64
Last 87 transactions
Buy: 7 685 070 \| Sell: 109 431

Histogen Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
GAINL	0.89
SVOK	0.885
TDAC	0.862
RMRM	0.86
APOP	0.847
ISNS	0.832
RNAZ	0.815

10 Labiausiai neigiamai susiję koreliacijos
BOCH	-0.936
SHSP	-0.877
MMAC	-0.841
NETE	-0.806

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Histogen Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$3.77M
Bruto pelnas:	$3.77M (100.00 %)
EPS:	$-3.26

FY	2022
Pajamos:	$3.77M
Bruto pelnas:	$3.77M (100.00 %)
EPS:	$-3.26

FY	2021
Pajamos:	$919 000
Bruto pelnas:	$699 000 (76.06 %)
EPS:	$-7.80

FY	2020
Pajamos:	$2.06M
Bruto pelnas:	$1.09M (52.99 %)
EPS:	$-41.60

Financial Reports:

No articles found.

Histogen Inc

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.